Download - Key Developments in PsA
Transcript
![Page 1: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/1.jpg)
Key Developments in PsA
![Page 2: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/2.jpg)
![Page 3: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/3.jpg)
Methods
![Page 4: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/4.jpg)
Findings in Patients With HAQ-DI > 0.5
![Page 5: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/5.jpg)
![Page 6: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/6.jpg)
Background
![Page 7: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/7.jpg)
Findings
![Page 8: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/8.jpg)
Key Developments in PsA
![Page 9: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/9.jpg)
![Page 10: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/10.jpg)
Methods
![Page 11: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/11.jpg)
![Page 12: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/12.jpg)
ResultsPatients Achieving PsARC Response
![Page 13: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/13.jpg)
![Page 14: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/14.jpg)
Findings
![Page 15: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/15.jpg)
Findings (cont)
![Page 16: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/16.jpg)
Key Developments in PsA
![Page 17: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/17.jpg)
![Page 18: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/18.jpg)
Methods
![Page 19: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/19.jpg)
FindingsWeek 16
![Page 20: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/20.jpg)
![Page 21: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/21.jpg)
![Page 22: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/22.jpg)
FindingsAEs and SAEs
![Page 23: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/23.jpg)
SafetyMost Common AEs
![Page 24: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/24.jpg)
Safety
![Page 25: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/25.jpg)
![Page 26: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/26.jpg)
Methods
![Page 27: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/27.jpg)
FindingsWeek 16, ACR20 and HAQ-DI
![Page 28: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/28.jpg)
FindingsPhysical Function, Week 52
![Page 29: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/29.jpg)
Key Developments in PsA
![Page 30: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/30.jpg)
![Page 31: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/31.jpg)
MethodsAssessing Disease Activity and Clinical Response
![Page 32: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/32.jpg)
Likelihood of Achieving Minimal Disease Activity at Week 48 Based
on Disease Activity/Clinical Response
![Page 33: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/33.jpg)
Likelihood of Achieving Remission at Week 48 Based on Disease
Activity/Clinical Response
![Page 34: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/34.jpg)
![Page 35: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/35.jpg)
Methods
![Page 36: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/36.jpg)
FindingsWeeks 28 and 52
![Page 37: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/37.jpg)
Abbreviations
![Page 38: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/38.jpg)
Abbreviations (cont)
![Page 39: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/39.jpg)
References
![Page 40: Key Developments in PsA](https://reader034.vdocument.in/reader034/viewer/2022052414/56813aec550346895da35907/html5/thumbnails/40.jpg)
References (cont)